Rufinamide

卢非酰胺

Report date: 2022/06/30 14:39:17
NMEFirst In Class

Base Information

Drug NameRufinamide
Drug Alias Name芦非酰胺rufinamidumrufinamida卢非醯胺Inovelon +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channels blockers
TargetsSodium channel alpha subunitSodium channels
Therapy Area/IndicationsAnxiety DisordersSeizuresLennox Gastaut Syndrome +[5] 
Global Approved IndicationsLennox Gastaut SyndromeEpilepsy
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2007/01/16
Country/TerritoryUnited StatesEUJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesEisai GmbhEisai IncEisai Co Ltd
Inactive CompaniesEisai LtdUniversity Of South AlabamaBiotie Therapies Inc
Active IndicationsSeizuresLennox Gastaut SyndromeEpilepsy
Inactive IndicationsAnxiety DisordersEpilepsies, Partial

Other Information

ATC CodeN03AF03
Related LinksWikipediaDrugBankKEGG